title: Protection by taurine against adriamycin-induced proteinuria and hyperlipidemia in rats.
abstract: Taurine was used in the present study to evaluate its beneficial effects against proteinuria and hyperlipidemia associated with nephrotic syndrome. Rats made nephrotic with adriamycin had a high excretion of protein, albumin, and N-acetyl-beta-D-glucosaminidase compared with nonnephrotic rats. Nephrotic rats manifested hyperlipidemia with significant elevation in all major lipoprotein fractions. Treatment with taurine significantly suppressed adriamycin-induced proteinuria, albuminuria, and urinary excretion of N-acetyl-beta-D-glucosaminidase. Treatment of rats wit taurine for 7 days before adriamycin, and daily thereafter, significantly lowered plasma cholesterol, triglycerides, phospholipids, lipid peroxides, and malondialdehyde associated with lipoprotein fractions. Similarly, total lipids, cholesterol, triglycerides, lipid peroxides, hydroperoxides, and hydroxyl radicals in the liver and kidneys of taurine-treated adriamycin rats were decreased significantly compared with adriamycin alone. Lecithin cholesterol acyl transferase activity and free fatty acid levels in plasma, lipoprotein lipase activity, glutathione, total thiol, and ascorbic acid in the liver and the kidneys of taurine-treated adriamycin groups were significantly elevated compared with adriamycin alone. These results suggest that taurine might be applicable as a protective agent for proteinuria and hyperlipidemia associated with nephrotic syndrome.
authors.affiliation: Department of Biochemistry, Central leather Research Institute, Madras, India.
authors.forename: N
authors.initials: N
authors.lastname: Venkatesan
authors.forename: P
authors.initials: P
authors.lastname: Venkatesan
authors.forename: J
authors.initials: J
authors.lastname: Karthikeyan
authors.forename: V
authors.initials: V
authors.lastname: Arumugam
mesh_terms: D000118:Acetylglucosaminidase / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D001835:Body Weight; D004317:Doxorubicin / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D006949:Hyperlipidemias / Q000517:prevention & control*; D008054:Lipid Peroxides / Q000097:blood; D008071:Lipoprotein Lipase / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D009404:Nephrotic Syndrome / Q000517:prevention & control*; D010084:Oxidation-Reduction; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000378:metabolism; D011507:Proteinuria / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D013654:Taurine / Q000494:pharmacology*
chemical_list: D000975:Antioxidants; D008054:Lipid Peroxides; D013654:Taurine; D004317:Doxorubicin; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D008071:Lipoprotein Lipase; D000118:Acetylglucosaminidase